Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INF904 open-label phase 2a basket study in chronic spontaneous urticaria or hidradenitis suppurativa
2024-515615-22-00Phase 2Completed
- Sponsor
- InflaRx
- Start
- Mar 2025
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, open-label trial of izicopan in chronic idiopathic urticaria (CIU) and hidradenitis suppurativa (HS) (2 cohorts), sponsored by InflaRx. Primary endpoint: Treatment-emergent adverse events and serious adverse events. Started Mar 2025; status: completed.
02
Drugs
izicopan
03
Conditions
chronic idiopathic urticaria (CIU)hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on 2024-515615-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515615-22-00.